Trial
NCT02413489
An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Janssen Research & Development, LLC
Collaborators
—
Condition
Lymphoma, Mantle-Cell
Intervention
Daratumumab
Why stopped
DLBCL and FL cohorts met the pre-specified futility criteria and will not proceed. The MCL cohort was terminated due to slow recruitment and aggressive disease.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-04